Paragonimiasis: diagnosis and the use of praziquantel in treatment.
Paragonimiasis was diagnosed in eight patients: five with sputum specimens positive for characteristic ova and three with only stool specimens positive for ova. Clinical symptoms, roentgenograms and serologic findings appeared to correlate with severity of disease. All eight patients were treated with praziquantel (oral dose, 75 mg/kg of body weight daily for two consecutive days). Of seven patients who completed the treatment, six had ova-negative sputum and stool specimens by day 90; the seventh patient's specimens became ova negative by day 120. The eighth patient, who had failed to respond to prior treatment with bithionol, could not tolerate the daily dosage of 75 mg/kg because of nausea. Although he received the same total dose (150 mg/kg) over four days his specimens remained ova positive on day 90. Adverse effects included nausea (two patients), headache (one patient), and urticaria (two), the last effect possibly secondary to release of antigen from drug-damaged parasites. A review of the epidemiology, clinical presentation, and treatment of pulmonary paragonimiasis is presented.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001210:Asia, Southeastern / Q000208:ethnology; D002648:Child; D004334:Drug Administration Schedule; D005243:Feces / Q000469:parasitology; D005260:Female; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008174:Lung Diseases, Parasitic / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010237:Paragonimiasis / Q000175:diagnosis / Q000188:drug therapy*; D010270:Parasite Egg Count; D011223:Praziquantel / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States
D007546:Isoquinolines; D011223:Praziquantel